apatinib plus camrelizumab

DRUG4 trials

Sponsors

Sun Yat-sen University, Peking Union Medical College Hospital, Ze-yang Ding, MD, Tongji Hospital

Conditions

Biliary Tract CancerBiomarkerChemotherapy EffectCholangiocarcinomaHepatobiliary NeoplasmHepatocellular Carcinoma Non-resectableImmunotherapyMetastatic Nasopharyngeal Carcinoma

Phase 2

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

Sun Yat-sen UniversityChemotherapy Effect, Immunotherapy, Metastatic Nasopharyngeal Carcinoma +3

Start: 2020-05-05End: 2023-09-05Updated: 2023-05-06

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer

CompletedNCT04642664

Peking Union Medical College HospitalBiliary Tract Cancer, Biomarker, Cholangiocarcinoma +1

Start: 2018-12-01End: 2021-01-01Updated: 2021-06-03

Unknown Phase

Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma

RecruitingNCT05713994

Ze-yang Ding, MDHepatocellular Carcinoma Non-resectable

Start: 2020-05-19End: 2025-12-30Target: 300Updated: 2025-03-25

Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma

RecruitingNCT05717738

Tongji HospitalHepatocellular Carcinoma Non-resectable

Start: 2022-01-20End: 2024-12-31Target: 300Updated: 2024-06-13

Related Papers

The Efficacy and Safety of Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer: A Prospective Clinical Study

Frontiers in Oncology2021-04-1252 citations